TUNG-HUNG SUTAI-CHUNG TSENGJIA-HORNG KAO2021-03-092021-03-0920180270-9139https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044319815&doi=10.1002%2fhep.29740&partnerID=40&md5=a88e0c93761b571b5272b3f785177d59https://scholars.lib.ntu.edu.tw/handle/123456789/551079[SDGs]SDG3circular DNA; covalently closed circular DNA; entecavir; unclassified drug; antivirus agent; alcohol liver disease; antiviral therapy; cancer incidence; cancer patient; cancer risk; chronic hepatitis B; Hepatitis B virus; human; Letter; liver cell; liver cell carcinoma; liver cirrhosis; mortality rate; patient risk; priority journal; treatment duration; vaccination; virus replication; chronic hepatitis B; Hepatitis B virus; liver cell carcinoma; liver tumor; treatment outcome; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Treatment OutcomeHCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed?letter10.1002/hep.29740292517892-s2.0-85044319815